399 related articles for article (PubMed ID: 21197148)
1. Pharmacotherapies for obesity: past, current, and future therapies.
Ioannides-Demos LL; Piccenna L; McNeil JJ
J Obes; 2011; 2011():179674. PubMed ID: 21197148
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for obesity.
Ioannides-Demos LL; Proietto J; McNeil JJ
Drugs; 2005; 65(10):1391-418. PubMed ID: 15977970
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak YJ; Lee SY
Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis: pharmacologic treatment of obesity.
Li Z; Maglione M; Tu W; Mojica W; Arterburn D; Shugarman LR; Hilton L; Suttorp M; Solomon V; Shekelle PG; Morton SC
Ann Intern Med; 2005 Apr; 142(7):532-46. PubMed ID: 15809465
[TBL] [Abstract][Full Text] [Related]
7. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
8. Anti-obesity drugs: a review about their effects and their safety.
Derosa G; Maffioli P
Expert Opin Drug Saf; 2012 May; 11(3):459-71. PubMed ID: 22439841
[TBL] [Abstract][Full Text] [Related]
9. Current and emerging pharmacotherapies for obesity in Australia.
Hocking S; Dear A; Cowley MA
Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
[TBL] [Abstract][Full Text] [Related]
10. Safety of antiobesity drugs.
Cheung BM; Cheung TT; Samaranayake NR
Ther Adv Drug Saf; 2013 Aug; 4(4):171-81. PubMed ID: 25114779
[TBL] [Abstract][Full Text] [Related]
11. Drug treatment of obesity: current status and future prospects.
Kakkar AK; Dahiya N
Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
13. New and emerging drug molecules against obesity.
George M; Rajaram M; Shanmugam E
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):65-76. PubMed ID: 24064009
[TBL] [Abstract][Full Text] [Related]
14. Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
Milano W; De Biasio V; Di Munzio W; Foggia G; Capasso A
Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1232-1243. PubMed ID: 32410565
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and safety of the new anti-obesity medications.
Hainer V; Aldhoon-Hainerová I
Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
Song JE; Ko HJ; Kim AS
Drug Des Devel Ther; 2024; 18():845-858. PubMed ID: 38524878
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy for obesity in individuals with type 2 diabetes.
Chukir T; Shukla AP; Saunders KH; Aronne LJ
Expert Opin Pharmacother; 2018 Feb; 19(3):223-231. PubMed ID: 29376439
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy for obesity.
Joo JK; Lee KS
J Menopausal Med; 2014 Dec; 20(3):90-6. PubMed ID: 25580419
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
